KATHERINE SCHULTHEISS: Open Payments
NPI 1558038901 · MESQUITE, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,575 in 119 payments from 15 companies in 2025. Trend: 2023 $1,170 · 2024 $1,649 · 2025 $2,575
Food & beverage: $2,575
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 47 | $873 |
| Janssen Biotech, Inc. | 20 | $500 |
| Gilead Sciences, Inc. | 9 | $203 |
| Ardelyx, Inc. | 6 | $157 |
| GENZYME CORPORATION | 5 | $153 |
| Madrigal Pharmaceuticals | 7 | $149 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $104 |
| Celltrion USA Inc. | 4 | $92 |
| Phathom Pharmaceuticals, Inc. | 4 | $89 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $69 |
Products named: RINVOQ, TREMFYA, IBSRELA, DUPIXENT, REZDIFFRA, CREON, MAVYRET, SKYRIZI.
Industry payments across TX — which companies pay providers there.
